奥克雷利祖马布暂时改变微生物群,并根据治疗结果调节免疫反应
Stepan Coufal1, Zuzana Jiraskova Zakostelska1, Tomas Thon1
1Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic.
iScience
|December 8, 2025
概括
多发性硬化症 (MS) 涉及肠道微生物群的变化,甚至在治疗之前. 抗CD20疗法对肠道细菌产生影响,反应者显示出改善的多样性和肠道屏障功能.
科学领域:
- 神经免疫学 神经免疫学
- 微生物组研究 微生物组研究
- 自免疫性疾病 自免疫性疾病
背景情况:
- 多发性硬化症 (MS) 是一种影响中枢神经系统的自身免疫性疾病.
- 微生物群失生与多发性硬化症的发病和治疗反应有关.
- 早期的多发性硬化和临床隔离综合征表现出不同的微生物特征.
研究的目的:
- 为了研究临床孤立综合征的未经治疗的个体的微生物群变化.
- 分析在MS患者的抗CD20治疗期间肠道细菌和病毒的动态变化.
- 探索肠道微生物群,肠道屏障功能和MS治疗结果之间的关系.
主要方法:
- 在肠道样本中分析细菌和病毒群落.
- 在12个月的抗CD20治疗中,对肠道微生物群组成的纵向评估.
- 测量肠道屏障生物标志物和对共生细菌的抗体.
主要成果:
- 在未接受过治疗的患有临床隔离综合征的个体中观察到微生物群的改变.
- 在抗CD20治疗的第一年,肠道细菌的变化是暂时的.
- 与非响应者相比,响应者表现出增加的肠道微生物群α多样性和改善的肠道屏障生物标志物.
结论:
- 肠道屏障损伤和微生物转移可能会导致MS的发病并影响治疗结果.
- 特定的细菌变化,如Parabacteroides spp.,与短链脂肪酸生产和肠道健康有关.
- 抗CD20疗法调节肠道微生物群和肠道屏障标志物,对治疗响应者和不响应者有不同的影响.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
461
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
461
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
413
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
413
Inflammatory Bowel Disease IV: Pharmacological Management
450
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
450
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
457
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
457
Drugs for Treatment of Ulcerative Colitis in IBD
431
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
431
Drugs for Treatment of Constipation-Predominant IBS
680
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
680


